8 December IPO Analysis: Wakefit vs. Corona Remedies – Which One Should You Buy? (2025 Edition)
Date: December 3, 2025
Category: Upcoming IPO Analysis / Stock Market 2025
Keywords: 8 December IPO list, Wakefit IPO GMP, Corona Remedies IPO Review, Best IPO to buy December 2025, Upcoming IPO India 2025[1][2]
Are you ready for "Super Monday" on December 8, 2025?
The primary market is heating up this winter with two major Mainboard IPOs and several SME issues opening on the same day. Investors have a tough choice: go with the popular D2C consumer brand Wakefit Innovations or the profitable pharmaceutical player Corona Remedies.
In this post, we provide a complete 360-degree analysis of both companies, including their Financials, Grey Market Premium (GMP), Risk Factors, and Final Verdict to help you decide where to park your money.
🚀 IPO #1: Wakefit Innovations Limited (The "Popular" Choice)
Focus: Direct-to-Consumer (D2C) Home & Sleep Solutions[2]
Wakefit is a household name in India, known for disrupting the mattress market with affordable memory foam products.[2] But is a good product a good stock?
1. Key IPO Details
IPO Open Date: December 8, 2025[1][2][3][4][5]
IPO Close Date: December 10, 2025[1][2][3][4][5][6][7]
Price Band: ₹185 – ₹195 per share[2][3][4][7][8]
Lot Size: 76 Shares (Min Investment: ₹14,820)[2][3][8]
Total Issue Size: ~₹1,288 Cr[3][4][7][8][9]
Listing On: BSE & NSE[1][3][4][5][8][10][11][12]
2. Financial Health Check (The "Red Flag")
Wakefit has shown impressive revenue growth, crossing the ₹1,300 Crore mark in FY25. However, profitability remains a concern.
Revenue (FY25): ₹1,305 Cr (Strong Growth)
Net Profit (FY25): Loss of ₹35 Cr ⚠️[8]
Trend: While revenue is up, the company is still burning cash to fuel its expansion into offline stores and furniture.
3. Grey Market Premium (GMP) Trends
Current GMP: ~₹36 per share[7][9]
Estimated Listing Gain: ~18% - 20%
Sentiment: Moderate. The brand is strong, but the loss-making status makes investors cautious.
4. SWOT Analysis
Strengths: Strong brand recall, data-driven marketing, rapid offline store expansion (125+ stores).
Weaknesses: Consistent losses, high marketing spend, competitive sector (competing with IKEA, Sleepwell).
Opportunities: Huge unorganized-to-organized market shift in Indian furniture.
Threats: Rising raw material costs (foam/timber) could further dent margins.
👉 Analyst Verdict for Wakefit:
Apply for Listing Gains (High Risk). Long-term wealth creation depends on when they turn profitable. Suitable for aggressive investors who believe in the D2C growth story.
💊 IPO #2: Corona Remedies Limited (The "Profitable" Choice)
Focus: Women's Health, Cardio-Diabetic, & Pain Management[5][13]
While less "glamorous" than Wakefit, Corona Remedies is a financial powerhouse in the pharma sector. It is growing faster than the Indian Pharmaceutical Market (IPM) average.
1. Key IPO Details
IPO Open Date: December 8, 2025[1][2][3][4][5][7]
IPO Close Date: December 10, 2025[1][2][3][4][5][6][7]
Price Band: ₹1,008 – ₹1,062 per share[1][6]
Lot Size: 14 Shares (Min Investment: ~₹14,868)[1]
Total Issue Size: ~₹655 Cr (100% Offer For Sale)
Listing On: BSE & NSE[1][3][4][5][8][10][11][12]
2. Financial Health Check (The "Green Flag")
Corona Remedies is a profit-generating machine with healthy margins.
Revenue (FY25): ₹1,196 Cr[6]
Net Profit (FY25): ₹149 Cr ✅
EBITDA Margin: ~20%
Trend: Consistent profit growth with a CAGR of 20% (vs industry avg of ~9%).
3. Grey Market Premium (GMP) Trends
Current GMP: ~₹307 per share[14]
Estimated Listing Gain: ~28% - 30%
Sentiment: Bullish. Investors love the combination of growth + profitability.
4. SWOT Analysis
Strengths: Leadership in women's healthcare, asset-light model, strong relationships with specialist doctors.
Weaknesses: 100% Offer For Sale (OFS) means money goes to selling shareholders, not the company.[13]
Opportunities: Expiring patents of big drugs allow for more branded generics.
Threats: Government price caps (NLEM) on essential medicines.
👉 Analyst Verdict for Corona Remedies:
Subscribe for Listing Gains & Long Term. The financials are robust, and the GMP indicates strong demand. It is the "safer" bet of the two.
⚡ Quick Look: SME IPOs Opening Dec 8
For high-risk, high-reward investors, three SME IPOs also open on this date:
Prodocs Solutions: IT/BPO services. Small issue size (~₹27 Cr).
K.V. Toys India: Toy manufacturing (benefiting from "China Plus One").
Riddhi Display Equipments: Retail fixtures and display solutions.
Note: SME IPOs require a minimum investment of ~₹1 Lakh+ and are highly volatile.
🏆 Final Conclusion: Wakefit or Corona?
| Sector | Consumer Tech / Home | Pharma |
| Profitability | ❌ Loss Making | ✅ Profitable |
| Risk Level | High | Low - Medium |
| Listing Gain Potential | ~18% | ~29% |
| Best For | Brand Lovers / Aggressive Traders | Conservative / Value Investors |
Our Recommendation:
If you have limited funds, prioritize Corona Remedies for its financial stability and higher GMP. If you have surplus capital, you can apply for Wakefit for potential listing pops due to brand hype, but keep a strict stop-loss if holding long-term.
❓ Frequently Asked Questions (FAQs)
Q: Which IPO opening on December 8 is best?
A: Financially, Corona Remedies is stronger because it is profitable. However, Wakefit has higher brand popularity.
Q: What is the GMP of Wakefit IPO today?
A: As of early December 2025, Wakefit's GMP is trading around ₹36, suggesting a premium of roughly 18-20%.
Q: Is Wakefit a loss-making company?
A: Yes, as of the FY25 financial data released in the RHP, Wakefit reported a net loss of approx ₹35 Cr, though its revenue grew significantly.
Q: Can I apply for both IPOs?
A: Yes, provided you have sufficient funds in your bank account and distinct mandates for each application.
Disclaimer: This post is for educational purposes only. GMP values are speculative and change daily. Please consult a SEBI-registered financial advisor before investing.[15]
No comments:
Post a Comment